4D MOLECULAR THERAPEUTICS IN (FDMT)
US35104E1001 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 275.59M | 249.11M | 52.40M | 153.00M | 276.70M | |||
| Marketable Securities | 250.32M | 39.12M | 161.20M | 94.80M | N/A | |||
| Receivables | N/A | N/A | 0.00 | 0.00 | 1.50M | |||
| Other Current Assets | 9.68M | 8.36M | 7.00M | 8.50M | 4.40M | |||
| Total Current Assets | 535.59M | 296.59M | 220.50M | 256.30M | 282.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 30.58M | 31.66M | 35.30M | 29.00M | 5.10M | |||
| Investments And Advances | 62.94M | 10.95M | 4.90M | 67.70M | N/A | |||
| Other Non-Current Assets | 771.00K | 684.00K | 1.10M | 600.00K | 600.00K | |||
| Total Non-Current Assets | 94.29M | 43.30M | 41.30M | 97.20M | 5.60M | |||
| TOTAL ASSETS | 629.88M | 339.89M | 261.80M | 353.50M | 288.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 10.74M | 13.58M | 10.10M | 7.40M | 4.80M | |||
| Accounts Payable | 4.22M | 3.52M | 3.30M | 4.80M | 1.80M | |||
| Other Current Liabilities | 1.45M | 1.85M | 2.30M | 4.20M | 10.20M | |||
| Total Current Liabilities | 16.40M | 18.95M | 15.70M | 16.30M | 16.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 12.92M | 13.11M | 14.80M | 18.00M | 15.20M | |||
| Total Non-Current Liabilities | 12.92M | 13.11M | 14.80M | 18.10M | 15.20M | |||
| TOTAL LIABILITIES | 29.32M | 32.06M | 30.50M | 34.40M | 31.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -447.73M | -415.33M | -314.50M | -207.00M | -135.70M | |||
| Additional Paid In Capital | 1.05B | 723.14M | 547.00M | 526.50M | 392.10M | |||
| Common Shares | 5.00K | 4.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -109.00K | 16.00K | -1.20M | -400.00K | N/A | |||
| Shares Outstanding | 51.16M | 43.08M | 32.60M | 32.20M | 26.70M | |||
| Tangible Book Value per Share | 11.74 | 7.15 | 7.10 | 9.91 | 9.60 | |||
| Total Shareholders' Equity | 600.56M | 307.83M | 231.30M | 319.10M | 256.40M | |||
| TOTAL LIABILITIES AND EQUITY | 629.88M | 339.89M | 261.80M | 353.50M | 288.30M | |||
| Statistics | ||||||||
| Current Ratio | 32.65 | 15.65 | 14.04 | 15.72 | 16.93 | |||
| Return On Assets (ROA) | -27.48% | -29.67% | -41.06% | -20.18% | -19.66% | |||
| Return On Equity (ROE) | -28.83% | -32.76% | -46.47% | -22.35% | -22.11% | |||
All data in USD